<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498368</url>
  </required_header>
  <id_info>
    <org_study_id>07-001944</org_study_id>
    <nct_id>NCT00498368</nct_id>
  </id_info>
  <brief_title>Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy</brief_title>
  <official_title>A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was about IgA nephropathy, a form of kidney disease characterized by the presence
      of blood and protein in the urine. This study was done to determine if the medication
      rituximab could reduce protein in the patient's urine.

      Hypothesis: In patients with progressive IgA nephropathy an intravenous infusion of 1000 mg
      of rituximab on Day 1 and Day 15 and Days 168 and 182 is superior to conventional therapy in
      reducing 24 hour proteinuria, and slowing progression of chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent clinical success in the use of Rituximab in the treatment of Lupus nephritis and other
      forms immune complex glomerulonephritis has led to its investigation in the treatment of IgA
      nephropathy. Because IgA class antibodies have comparatively short half-lives and that
      deposition of polymeric forms of IgA contributes to glomerular injury, the researchers
      speculated that the reduction of circulating IgA could reduce proteinuria and injury in
      patients with IgA nephropathy.

      Treatment and Follow-up:

      Subjects were randomly assigned to receive rituximab or to continue standard care. Both arms
      received a Omega-3 Fatty Acid Fish Oil Supplement and angiotensin converting enzyme (ACE)
      inhibitors and/or Angiotensin II receptor blockers (ARBs). ACE inhibitors and/or ARBs were
      used to achieve a blood pressure goal of &lt;130/80 mmHg.

      The study was an open-label trial; those assigned to rituximab received a 1 g infusion of
      rituximab followed by an identical dose 2 weeks later. Premedication with corticosteroids (10
      mg dexamethasone intravenously) was also given 30 min prior to the first infusion of each
      series of rituximab. They received an identical 2 g course of rituximab 6 months later.
      Subjects were assessed at least every 3 months or as needed for clinical events. This
      assessment included physical examination, a questionnaire for adverse events, and measurement
      of routine hematology, serum chemistry, timed urine protein excretion, and for those assigned
      to rituximab, B-cell subsets. Follow-up was considered complete at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Proteinuria at 12 Months</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Marker IgA at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Marker Gd-Immunoglobulin A Subclass 1 (IgA1) at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Marker Immunoglobulin G (IgG) AutoAb at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Rituximab Plus ACE/ARB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE/ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Rituximab</intervention_name>
    <description>Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182</description>
    <arm_group_label>Rituximab Plus ACE/ARB</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE/ARB</intervention_name>
    <description>ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of &lt;130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB</description>
    <arm_group_label>Rituximab Plus ACE/ARB</arm_group_label>
    <arm_group_label>ACE/ARB</arm_group_label>
    <other_name>Angiotensin II blockade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 Fatty Acid Fish Oil Supplement</intervention_name>
    <description>Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
    <arm_group_label>Rituximab Plus ACE/ARB</arm_group_label>
    <arm_group_label>ACE/ARB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient between the age of 18 and 70 years of age and able to give informed
             consent

          -  GFR by Cockcroft-Gault or MDRD equations &lt;90 mls/min and &gt;30 mls/min

          -  Greater than or equal to 1000 mg of proteinuria/24 hours while on stable ACEi, ARB or
             renin inhibitor therapy for 2 months. Patients receiving combination ACE or ARB or
             ACEi and a renin inhibitor for 2 months will only require 500mg/24 hours

          -  Blood pressure &lt;130/80 mmHg. The presence of hypertension is not required for study
             entry, but any patient requiring long term hypertensive medications must have blood
             pressure controlled &lt;130-80 mmHg, to be considered eligible for the study

          -  Female patients with IgA will be considered eligible for study entry if they have a
             negative urine or serum pregnancy test at the time of screening are agreeable to 2
             years of contraception

          -  Biopsy proven IgA nephropathy and clinical features consistent with Henoch Schonlein
             Purpura will be considered eligible for the study

          -  Able to swallow the oral medications

        Exclusion Criteria

          -  Clinical and histologic evidence of IgA predominant Lupus nephritis

          -  Clinical and histologic evidence of idiopathic IgA forms of membranoproliferative
             glomerulonephritis

          -  Clinical evidence of cirrhosis, chronic active liver disease or known infection with
             hepatitis B, C or HIV

          -  Estimated GFR &lt;30 ml/min/1.73mÂ² at the time of screening

          -  Greater than 50% glomerular senescence or cortical scarring on renal biopsy

          -  Active systemic infection or history of serious infection within one month of entry

          -  History of Crohn's disease or Celiac Sprue

          -  Positive pregnancy test or breast feeding at time of study entry or unwilling to
             comply with contraceptive measures

          -  Current or recent (within 30 days) exposure to any investigational drug

          -  Serum Cr &gt;3.5 mg/dl or Modification of Diet in Renal Disease (MDRD) calculated GFR &lt;30
             mls/min

          -  Patients receiving &gt;6 months therapy with oral prednisone or glucocorticoid equivalent

          -  Live vaccine within 28 days of study enrollment.

        General Safety &amp; Laboratory Exclusion Criteria

          -  Patients with anaphylaxis and/or known allergic reactions to Rituximab

          -  Hemoglobin: &lt;8.5 gm/dL

          -  Platelets: &lt;100,000/mm

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5 x Upper Limit
             of Normal unless related to primary disease.

          -  Previous Treatment with Rituximab(MabTheraÂ®/RituxanÂ®)

          -  Previous treatment with Natalizumab(TysabriÂ®)

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies

          -  History of recurrent significant infection or recurrent bacterial infections

          -  Known active bacterial, viral fungal mycobacterial or atypical mycobacterial
             infections, but excluding fungal infections of nail beds

          -  Any major episode of infection requiring hospitalization or treatment with i.v.
             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to
             screening

          -  Ongoing use of high dose steroids(&gt;10 mg/day)or unstable steroid dose in the past 4
             weeks

          -  Lack of peripheral venous access

          -  History of drug, alcohol, or chemical abuse within 6 months prior to screening

          -  Pregnancy (a negative serum or urine pregnancy test will be performed for all women of
             childbearing potential no later than 7 days prior to treatment) or lactation

          -  Concomitant or previous malignancies, with the exception of adequately treated basal
             or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

          -  History of psychiatric disorder that would interfere with normal participation in this
             protocol

          -  Significant cardiac or pulmonary disease (including obstructive pulmonary disease)

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complication

          -  Inability to comply with study and follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando C. Fervenza, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Ohio</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.</citation>
    <PMID>27821627</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>September 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2016</results_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Fernando Fervenza</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Estimated glomerular filtration rate (GFR)</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Renal Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rituximab Plus ACE/ARB</title>
          <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
Intravenous Rituximab: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182
An angiotensin converting enzyme (ACE) inhibitors and /or angiotensin II receptor blockers (ARBs) will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
        </group>
        <group group_id="P2">
          <title>ACE/ARB</title>
          <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab Plus ACE/ARB</title>
          <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
Intravenous Rituximab: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182
An ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
        </group>
        <group group_id="B2">
          <title>ACE/ARB</title>
          <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="29" upper_limit="63"/>
                    <measurement group_id="B2" value="33" lower_limit="21" upper_limit="59"/>
                    <measurement group_id="B3" value="40" lower_limit="21" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Proteinuria at 12 Months</title>
        <time_frame>1 year</time_frame>
        <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab Plus ACE/ARB</title>
            <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
Intravenous Rituximab: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182
An angiotensin converting enzyme (ACE) inhibitors and /or angiotensin II receptor blockers (ARBs) will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
          <group group_id="O2">
            <title>ACE/ARB</title>
            <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proteinuria at 12 Months</title>
          <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with &gt; 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with &gt;50% increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with &lt;500 mg of protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Marker IgA at 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab Plus ACE/ARB</title>
            <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
Intravenous Rituximab: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182
An angiotensin converting enzyme (ACE) inhibitors and /or angiotensin II receptor blockers (ARBs) will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
          <group group_id="O2">
            <title>ACE/ARB</title>
            <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Marker IgA at 12 Months</title>
          <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.4"/>
                    <measurement group_id="O2" value="4.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Marker Gd-Immunoglobulin A Subclass 1 (IgA1) at 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab Plus ACE/ARB</title>
            <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
Intravenous Rituximab: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182
An angiotensin converting enzyme (ACE) inhibitors and /or angiotensin II receptor blockers (ARBs) will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
          <group group_id="O2">
            <title>ACE/ARB</title>
            <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Marker Gd-Immunoglobulin A Subclass 1 (IgA1) at 12 Months</title>
          <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
          <units>U/100ng IgA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" spread="13.0"/>
                    <measurement group_id="O2" value="58.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Marker Immunoglobulin G (IgG) AutoAb at 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab Plus ACE/ARB</title>
            <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
Intravenous Rituximab: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182
An angiotensin converting enzyme (ACE) inhibitors and /or angiotensin II receptor blockers (ARBs) will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
          <group group_id="O2">
            <title>ACE/ARB</title>
            <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Marker Immunoglobulin G (IgG) AutoAb at 12 Months</title>
          <population>The number of participants differs from the participant flow because not all participants had the laboratory test done.</population>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1751.3" spread="2469.4"/>
                    <measurement group_id="O2" value="1075" spread="908.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rituximab Plus ACE/ARB</title>
          <description>Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
Intravenous Rituximab: Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182
An angiotensin converting enzyme (ACE) inhibitors and /or angiotensin II receptor blockers (ARBs) will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
        </group>
        <group group_id="E2">
          <title>ACE/ARB</title>
          <description>ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
ACE/ARB: ACE inhibitors and /or ARBs will be used to achieve a B/P goal of &lt;130/80 millimeters of mercury (mmHg)
Omega-3 Fatty Acid Fish Oil Supplement: Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fernando Fervenza</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-3712</phone>
      <email>Fervenza.Fernando@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

